CA1103239A - Product and process for treating schizophrenia - Google Patents

Product and process for treating schizophrenia

Info

Publication number
CA1103239A
CA1103239A CA273,825A CA273825A CA1103239A CA 1103239 A CA1103239 A CA 1103239A CA 273825 A CA273825 A CA 273825A CA 1103239 A CA1103239 A CA 1103239A
Authority
CA
Canada
Prior art keywords
amino acid
carbon atoms
moiety
threonyl
blocked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA273,825A
Other languages
English (en)
French (fr)
Inventor
Charles E. Frohman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
State of Michigan
Original Assignee
State of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/772,851 external-priority patent/US4146614A/en
Application filed by State of Michigan filed Critical State of Michigan
Application granted granted Critical
Publication of CA1103239A publication Critical patent/CA1103239A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA273,825A 1976-03-23 1977-03-11 Product and process for treating schizophrenia Expired CA1103239A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66952676A 1976-03-23 1976-03-23
US669,526 1976-03-23
US772,851 1977-02-28
US05/772,851 US4146614A (en) 1976-03-23 1977-02-28 Threonyl-valyline leucine containing peptides and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CA1103239A true CA1103239A (en) 1981-06-16

Family

ID=27100128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA273,825A Expired CA1103239A (en) 1976-03-23 1977-03-11 Product and process for treating schizophrenia

Country Status (13)

Country Link
JP (1) JPS52142015A (da)
AU (1) AU510679B2 (da)
CA (1) CA1103239A (da)
DE (1) DE2712781A1 (da)
DK (1) DK125177A (da)
FR (1) FR2351954A1 (da)
GB (1) GB1561247A (da)
GR (1) GR63642B (da)
LU (1) LU76998A1 (da)
NL (1) NL7703124A (da)
NO (1) NO771031L (da)
NZ (1) NZ183627A (da)
SE (1) SE7702925L (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501147A (ja) * 1984-12-14 1987-05-07 オーストラリアン　コマーシャル　リサーチ　アンド　ディベロップメント　リミティド ヒト白血球エラスタ−ゼのアミノ酸阻害剤及びペプチド阻害剤
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬

Also Published As

Publication number Publication date
NZ183627A (en) 1980-02-21
FR2351954B1 (da) 1980-03-28
JPS52142015A (en) 1977-11-26
SE7702925L (sv) 1977-09-24
GR63642B (en) 1979-11-27
NL7703124A (nl) 1977-09-27
NO771031L (no) 1977-09-26
LU76998A1 (da) 1977-10-03
GB1561247A (en) 1980-02-13
DE2712781A1 (de) 1977-10-06
FR2351954A1 (fr) 1977-12-16
AU510679B2 (en) 1980-07-10
DK125177A (da) 1977-09-24
AU2317477A (en) 1978-09-14

Similar Documents

Publication Publication Date Title
US4229438A (en) Nonapeptides
JP2945680B2 (ja) ペプチド誘導体およびその用途
CA1248699A (en) Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them and methods for treating ulcer and thrombus with them
JPS63215696A (ja) 新規ペプチドおよびこのペプチドを含む血栓治療剤
CA1282550C (en) Methods and compositions for preparation of h-arg-x-z-y-tyr-r
US3842064A (en) Psychopharmacologically active tetra-,penta-,hexa-,and hepta-peptides
CA1105006A (en) Peptides
US3912705A (en) Thyrotropin releasing hormone analogs
Sakakibara et al. A synthesis of oxytocin
CA1103239A (en) Product and process for treating schizophrenia
Li et al. The synthesis of L-histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their melanocyte-stimulating activity
US3770715A (en) Acth active peptides having d serine as first aminoacid from n terminus and l ornithine as11 aminoacid
US4748154A (en) Peptide derivatives, their production and use
US3872074A (en) Method for the aminolysis of activated esters in the presence of N-hydroxy compounds as catalysts
US4146614A (en) Threonyl-valyline leucine containing peptides and pharmaceutical compositions
EP0080283B1 (en) N-carboxyalkylproline-containing tripeptides
JPS60231697A (ja) ペプチド
US4551273A (en) Analgesic peptide and process for the preparation thereof
US3272790A (en) Polypeptides
Seu et al. Synthesis of Isoleucyl 5-alanyl 7-angiotensin II
US4315853A (en) Polyprenylpeptides and their production
US4172130A (en) α-AMINOACYL CONTAINING NEW PEPTIDES WITH GASTRIN EFFECTS AND A PROCESS FOR THE PREPARATION THEREOF
Diaz et al. A large-scale synthesis of somatostatin for clinical use by a novel alternating solution/solid-phase procedure
JPH0414120B2 (da)
US4382923A (en) Tetrapeptide acylhydrazides, their production and use

Legal Events

Date Code Title Description
MKEX Expiry
MKEX Expiry

Effective date: 19980616